ID   PA2GA_HUMAN             Reviewed;         144 AA.
AC   P14555; A8K5I7; Q6DN24; Q6IBD9; Q9UCD2;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 2.
DT   10-MAY-2017, entry version 196.
DE   RecName: Full=Phospholipase A2, membrane associated;
DE            EC=3.1.1.4 {ECO:0000269|PubMed:2925633};
DE   AltName: Full=GIIC sPLA2;
DE   AltName: Full=Group IIA phospholipase A2;
DE   AltName: Full=Non-pancreatic secretory phospholipase A2;
DE            Short=NPS-PLA2;
DE   AltName: Full=Phosphatidylcholine 2-acylhydrolase 2A;
DE   Flags: Precursor;
GN   Name=PLA2G2A; Synonyms=PLA2B, PLA2L, RASF-A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RC   TISSUE=Rheumatoid arthritic synovial fluid;
RX   PubMed=2925608;
RA   Seilhamer J.J., Pruzanski W., Vadas P., Plant S., Miller J.A.,
RA   Kloss J., Johnson L.K.;
RT   "Cloning and recombinant expression of phospholipase A2 present in
RT   rheumatoid arthritic synovial fluid.";
RL   J. Biol. Chem. 264:5335-5338(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 21-39,
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND SUBCELLULAR LOCATION.
RX   PubMed=2925633;
RA   Kramer R.M., Hession C., Johansen B., Hayes G., McGray P., Chow E.P.,
RA   Tizard R., Pepinsky R.B.;
RT   "Structure and properties of a human non-pancreatic phospholipase
RT   A2.";
RL   J. Biol. Chem. 264:5768-5775(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2239446;
RA   Kramer R.M., Johansen B., Hession C., Pepinsky R.B.;
RT   "Structure and properties of a secretable phospholipase A2 from human
RT   platelets.";
RL   Adv. Exp. Med. Biol. 275:35-53(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RA   Liang N.S., Fang Z.W., Li Y., Yang F., Lu Y., Xie Y.A.;
RT   "Cloning and sequence determination of human platelet phospholipase A2
RT   from liver tissues.";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT TYR-19.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 21-144, AND SUBCELLULAR LOCATION.
RC   TISSUE=Spleen;
RX   PubMed=2775276; DOI=10.1016/0006-291X(89)92096-2;
RA   Kanda A., Ono T., Yoshida N., Tojo H., Okamoto M.;
RT   "The primary structure of a membrane-associated phospholipase A2 from
RT   human spleen.";
RL   Biochem. Biophys. Res. Commun. 163:42-48(1989).
RN   [12]
RP   PROTEIN SEQUENCE OF 21-54.
RC   TISSUE=Synovial fluid;
RX   PubMed=3240982; DOI=10.1093/oxfordjournals.jbchem.a122467;
RA   Hara S., Kudo I., Matsuta K., Miyamoto T., Inoue K.;
RT   "Amino acid composition and NH2-terminal amino acid sequence of human
RT   phospholipase A2 purified from rheumatoid synovial fluid.";
RL   J. Biochem. 104:326-328(1988).
RN   [13]
RP   PROTEIN SEQUENCE OF 21-33.
RC   TISSUE=Synovial fluid;
RX   PubMed=3202859; DOI=10.1016/S0006-291X(88)80275-4;
RA   Lai C.Y., Wada K.;
RT   "Phospholipase A2 from human synovial fluid: purification and
RT   structural homology to the placental enzyme.";
RL   Biochem. Biophys. Res. Commun. 157:488-493(1988).
RN   [14]
RP   PROTEIN SEQUENCE OF 21-75.
RC   TISSUE=Ileal mucosa;
RX   PubMed=8399335;
RA   Minami T., Tojo H., Shinomura Y., Matsuzawa Y., Okamoto M.;
RT   "Purification and characterization of a phospholipase A2 from human
RT   ileal mucosa.";
RL   Biochim. Biophys. Acta 1170:125-130(1993).
RN   [15]
RP   FUNCTION, AND MUTAGENESIS OF ARG-62; HIS-67; ARG-73; ARG-94 AND
RP   ARG-120.
RX   PubMed=18635536; DOI=10.1074/jbc.M804835200;
RA   Saegusa J., Akakura N., Wu C.Y., Hoogland C., Ma Z., Lam K.S.,
RA   Liu F.T., Takada Y.K., Takada Y.;
RT   "Pro-inflammatory secretory phospholipase A2 type IIA binds to
RT   integrins alphavbeta3 and alpha4beta1 and induces proliferation of
RT   monocytic cells in an integrin-dependent manner.";
RL   J. Biol. Chem. 283:26107-26115(2008).
RN   [16]
RP   INHIBITION OF INTEGRIN BINDING.
RX   PubMed=23164706; DOI=10.1016/j.bmcl.2012.10.080;
RA   Ye L., Dickerson T., Kaur H., Takada Y.K., Fujita M., Liu R.,
RA   Knapp J.M., Lam K.S., Schore N.E., Kurth M.J., Takada Y.;
RT   "Identification of inhibitors against interaction between pro-
RT   inflammatory sPLA2-IIA protein and integrin alphavbeta3.";
RL   Bioorg. Med. Chem. Lett. 23:340-345(2013).
RN   [17]
RP   FUNCTION, AND MUTAGENESIS OF GLY-49; HIS-67; ASP-68; ARG-94 AND
RP   ARG-120.
RX   PubMed=25398877; DOI=10.1074/jbc.M114.579946;
RA   Fujita M., Zhu K., Fujita C.K., Zhao M., Lam K.S., Kurth M.J.,
RA   Takada Y.K., Takada Y.;
RT   "Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces
RT   integrin activation through direct binding to a newly identified
RT   binding site (site 2) in integrins alphavbeta3, alpha4beta1, and
RT   alpha5beta1.";
RL   J. Biol. Chem. 290:259-271(2015).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   PubMed=2062381; DOI=10.1038/352079a0;
RA   Wery J.-P., Schevitz R.W., Clawson D.K., Bobbitt J.L., Dow E.R.,
RA   Gamboa G., Goodson T. Jr., Hermann R.B., Kramer R.M., McClure D.B.,
RA   Mihelich E.D., Putnam J.E., Sharp J.D., Stark D.H., Teater C.,
RA   Warrick M.W., Jones N.D.;
RT   "Structure of recombinant human rheumatoid arthritic synovial fluid
RT   phospholipase A2 at 2.2-A resolution.";
RL   Nature 352:79-82(1991).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   PubMed=1948070; DOI=10.1126/science.1948070;
RA   Scott D.L., White S.P., Browning J.L., Rosa J.J., Gelb M.H.,
RA   Sigler P.B.;
RT   "Structures of free and inhibited human secretory phospholipase A2
RT   from inflammatory exudate.";
RL   Science 254:1007-1010(1991).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   PubMed=7664108; DOI=10.1038/nsb0695-458;
RA   Schevitz R.W., Bach N.J., Carlson D.G., Chirgadze N.Y., Clawson D.K.,
RA   Dillard R.D., Draheim S.E., Hartley L.W., Jones N.D., Mihelich E.D.,
RA   Olkowski J.L., Snyder D.W., Dand S.C., Wery J.-P.;
RT   "Structure-based design of the first potent and selective inhibitor of
RT   human non-pancreatic secretory phospholipase A2.";
RL   Nat. Struct. Biol. 2:458-465(1995).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   PubMed=9538252; DOI=10.1093/oxfordjournals.jbchem.a021982;
RA   Kitadokoro K., Hagishita S., Sato T., Ohtan M., Miki K.;
RT   "Crystal structure of human secretory phospholipase A2-IIA complex
RT   with the potent indolizine inhibitor 120-1032.";
RL   J. Biochem. 123:619-623(1998).
CC   -!- FUNCTION: Catalyzes the calcium-dependent hydrolysis of the 2-acyl
CC       groups in 3-sn-phosphoglycerides (PubMed:2925633). Thought to
CC       participate in the regulation of phospholipid metabolism in
CC       biomembranes including eicosanoid biosynthesis. Independent of its
CC       catalytic activity, acts as a ligand for integrins
CC       (PubMed:18635536, PubMed:25398877). Binds to and activates
CC       integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1
CC       (PubMed:18635536, PubMed:25398877). Binds to a site (site 2) which
CC       is distinct from the classical ligand-binding site (site 1) and
CC       induces integrin conformational changes and enhanced ligand
CC       binding to site 1 (PubMed:25398877). Induces cell proliferation in
CC       an integrin-dependent manner (PubMed:18635536).
CC       {ECO:0000269|PubMed:18635536, ECO:0000269|PubMed:25398877,
CC       ECO:0000269|PubMed:2925633}.
CC   -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-
CC       acylglycerophosphocholine + a carboxylate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10035, ECO:0000255|PROSITE-ProRule:PRU10036,
CC       ECO:0000269|PubMed:2925633}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:2925633};
CC       Note=Binds 1 Ca(2+) ion per subunit.;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Peripheral
CC       membrane protein {ECO:0000269|PubMed:2775276}. Secreted
CC       {ECO:0000269|PubMed:2925608, ECO:0000269|PubMed:2925633}.
CC   -!- MISCELLANEOUS: Group II phospholipase A2 is found in many cells
CC       and also extracellularly. The membrane-bound and secreted forms
CC       are identical and are encoded by a single gene.
CC   -!- MISCELLANEOUS: Interaction with integrin ITGA4:ITGB3 is inhibited
CC       by a number of synthetic peptides including R-Ala-Trp-Asp-Ile and
CC       R-Gly-Arg-Gly-Asp-Asp-Asp which bind to PLA2G2A and disrupt its
CC       integrin-binding activity. {ECO:0000269|PubMed:23164706}.
CC   -!- SIMILARITY: Belongs to the phospholipase A2 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pla2g2a/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PLA2G2AID41730ch1p36.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22430; AAA36550.1; -; mRNA.
DR   EMBL; M22431; AAA36549.1; -; Genomic_DNA.
DR   EMBL; AY656695; AAT73043.1; -; mRNA.
DR   EMBL; CR456865; CAG33146.1; -; mRNA.
DR   EMBL; AY462114; AAR16084.1; -; Genomic_DNA.
DR   EMBL; AL358253; CAH74017.1; -; Genomic_DNA.
DR   EMBL; AK291302; BAF83991.1; -; mRNA.
DR   EMBL; CH471134; EAW94907.1; -; Genomic_DNA.
DR   EMBL; BC005919; AAH05919.1; -; mRNA.
DR   CCDS; CCDS201.1; -.
DR   PIR; A32862; PSHUYF.
DR   RefSeq; NP_000291.1; NM_000300.3.
DR   RefSeq; NP_001155199.1; NM_001161727.1.
DR   RefSeq; NP_001155200.1; NM_001161728.1.
DR   RefSeq; NP_001155201.1; NM_001161729.1.
DR   UniGene; Hs.466804; -.
DR   PDB; 1AYP; X-ray; 2.57 A; A/B/C/D/E/F=21-144.
DR   PDB; 1BBC; X-ray; 2.20 A; A=21-144.
DR   PDB; 1DB4; X-ray; 2.20 A; A=21-144.
DR   PDB; 1DB5; X-ray; 2.80 A; A=21-144.
DR   PDB; 1DCY; X-ray; 2.70 A; A=21-144.
DR   PDB; 1J1A; X-ray; 2.20 A; A/B=21-144.
DR   PDB; 1KQU; X-ray; 2.10 A; A=21-144.
DR   PDB; 1KVO; X-ray; 2.00 A; A/B/C/D/E/F=21-144.
DR   PDB; 1N28; X-ray; 1.50 A; A/B=21-144.
DR   PDB; 1N29; X-ray; 2.60 A; A=21-144.
DR   PDB; 1POD; X-ray; 2.10 A; A=21-144.
DR   PDB; 1POE; X-ray; 2.10 A; A/B=21-144.
DR   PDB; 2GNY; Model; -; A=21-144.
DR   PDB; 3U8B; X-ray; 2.30 A; A=21-144.
DR   PDB; 3U8D; X-ray; 1.80 A; A/B=21-144.
DR   PDB; 3U8H; X-ray; 2.30 A; A/B=21-144.
DR   PDB; 3U8I; X-ray; 1.10 A; A/B=21-144.
DR   PDB; 5G3N; X-ray; 1.80 A; A/B=21-144.
DR   PDBsum; 1AYP; -.
DR   PDBsum; 1BBC; -.
DR   PDBsum; 1DB4; -.
DR   PDBsum; 1DB5; -.
DR   PDBsum; 1DCY; -.
DR   PDBsum; 1J1A; -.
DR   PDBsum; 1KQU; -.
DR   PDBsum; 1KVO; -.
DR   PDBsum; 1N28; -.
DR   PDBsum; 1N29; -.
DR   PDBsum; 1POD; -.
DR   PDBsum; 1POE; -.
DR   PDBsum; 2GNY; -.
DR   PDBsum; 3U8B; -.
DR   PDBsum; 3U8D; -.
DR   PDBsum; 3U8H; -.
DR   PDBsum; 3U8I; -.
DR   PDBsum; 5G3N; -.
DR   ProteinModelPortal; P14555; -.
DR   SMR; P14555; -.
DR   BioGrid; 111337; 26.
DR   IntAct; P14555; 3.
DR   MINT; MINT-1206447; -.
DR   STRING; 9606.ENSP00000364252; -.
DR   BindingDB; P14555; -.
DR   ChEMBL; CHEMBL3474; -.
DR   DrugBank; DB04287; (S)-5-(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoylamino)-Pentanoic Acid.
DR   DrugBank; DB03121; 1-Benzyl-5-Methoxy-2-Methyl-1h-Indol-3-Yl)-Acetic Acid.
DR   DrugBank; DB04112; 1-Octadecyl-2-Acetamido-2-Deoxy-Sn-Glycerol-3-Phosphoethylmethyl Sulfide.
DR   DrugBank; DB02936; 4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid.
DR   DrugBank; DB03471; 6-Phenyl-4(R)-(7-Phenyl-Heptanoylamino)-Hexanoic Acid.
DR   DrugBank; DB02504; [3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB03784; Elaidoylamide.
DR   DrugBank; DB01381; Ginkgo biloba.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB02325; Isopropyl Alcohol.
DR   DrugBank; DB03017; Lauric Acid.
DR   DrugBank; DB02448; N-Tridecanoic Acid.
DR   DrugBank; DB04786; Suramin.
DR   GuidetoPHARMACOLOGY; 1417; -.
DR   SwissLipids; SLP:000000653; -.
DR   iPTMnet; P14555; -.
DR   PhosphoSitePlus; P14555; -.
DR   BioMuta; PLA2G2A; -.
DR   DMDM; 129483; -.
DR   PaxDb; P14555; -.
DR   PeptideAtlas; P14555; -.
DR   PRIDE; P14555; -.
DR   DNASU; 5320; -.
DR   Ensembl; ENST00000375111; ENSP00000364252; ENSG00000188257.
DR   Ensembl; ENST00000400520; ENSP00000383364; ENSG00000188257.
DR   GeneID; 5320; -.
DR   KEGG; hsa:5320; -.
DR   UCSC; uc001bcv.4; human.
DR   CTD; 5320; -.
DR   DisGeNET; 5320; -.
DR   GeneCards; PLA2G2A; -.
DR   HGNC; HGNC:9031; PLA2G2A.
DR   HPA; HPA015236; -.
DR   MalaCards; PLA2G2A; -.
DR   MIM; 172411; gene.
DR   neXtProt; NX_P14555; -.
DR   OpenTargets; ENSG00000188257; -.
DR   PharmGKB; PA270; -.
DR   eggNOG; KOG4087; Eukaryota.
DR   eggNOG; ENOG411283D; LUCA.
DR   GeneTree; ENSGT00760000119160; -.
DR   HOGENOM; HOG000231749; -.
DR   HOVERGEN; HBG008137; -.
DR   InParanoid; P14555; -.
DR   KO; K01047; -.
DR   OMA; KQDSCRS; -.
DR   OrthoDB; EOG091G0UZ3; -.
DR   PhylomeDB; P14555; -.
DR   TreeFam; TF319283; -.
DR   BRENDA; 3.1.1.4; 2681.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482801; Acyl chain remodelling of PS.
DR   Reactome; R-HSA-1482839; Acyl chain remodelling of PE.
DR   Reactome; R-HSA-1482922; Acyl chain remodelling of PI.
DR   Reactome; R-HSA-1482925; Acyl chain remodelling of PG.
DR   Reactome; R-HSA-1483166; Synthesis of PA.
DR   Reactome; R-HSA-6803157; Antimicrobial peptides.
DR   ChiTaRS; PLA2G2A; human.
DR   EvolutionaryTrace; P14555; -.
DR   GeneWiki; PLA2G2A; -.
DR   GenomeRNAi; 5320; -.
DR   PRO; PR:P14555; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000188257; -.
DR   CleanEx; HS_PLA2G2A; -.
DR   ExpressionAtlas; P14555; baseline and differential.
DR   Genevisible; P14555; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:LIFEdb.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030141; C:secretory granule; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0047498; F:calcium-dependent phospholipase A2 activity; TAS:UniProtKB.
DR   GO; GO:0004623; F:phospholipase A2 activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0019730; P:antimicrobial humoral response; TAS:Reactome.
DR   GO; GO:0050482; P:arachidonic acid secretion; IEA:InterPro.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; TAS:BHF-UCL.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; TAS:BHF-UCL.
DR   GO; GO:0006654; P:phosphatidic acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0046473; P:phosphatidic acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036152; P:phosphatidylethanolamine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036148; P:phosphatidylglycerol acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036149; P:phosphatidylinositol acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036150; P:phosphatidylserine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0006644; P:phospholipid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:CACAO.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; TAS:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; TAS:BHF-UCL.
DR   CDD; cd00125; PLA2c; 1.
DR   Gene3D; 1.20.90.10; -; 1.
DR   InterPro; IPR001211; PLipase_A2.
DR   InterPro; IPR033112; PLipase_A2_Asp_AS.
DR   InterPro; IPR016090; PLipase_A2_dom.
DR   InterPro; IPR033113; PLipase_A2_His_AS.
DR   PANTHER; PTHR11716; PTHR11716; 1.
DR   Pfam; PF00068; Phospholip_A2_1; 1.
DR   PRINTS; PR00389; PHPHLIPASEA2.
DR   SMART; SM00085; PA2c; 1.
DR   SUPFAM; SSF48619; SSF48619; 1.
DR   PROSITE; PS00119; PA2_ASP; 1.
DR   PROSITE; PS00118; PA2_HIS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Hydrolase;
KW   Lipid degradation; Lipid metabolism; Membrane; Metal-binding;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     20       {ECO:0000269|PubMed:2775276,
FT                                ECO:0000269|PubMed:2925633,
FT                                ECO:0000269|PubMed:3202859,
FT                                ECO:0000269|PubMed:3240982,
FT                                ECO:0000269|PubMed:8399335}.
FT   CHAIN        21    144       Phospholipase A2, membrane associated.
FT                                /FTId=PRO_0000022750.
FT   ACT_SITE     67     67       {ECO:0000250}.
FT   ACT_SITE    111    111       {ECO:0000250}.
FT   METAL        47     47       Calcium; via carbonyl oxygen.
FT   METAL        49     49       Calcium; via carbonyl oxygen.
FT   METAL        51     51       Calcium; via carbonyl oxygen.
FT   METAL        68     68       Calcium.
FT   SITE         94     94       Important for integrin binding.
FT                                {ECO:0000269|PubMed:18635536}.
FT   SITE        120    120       Important for integrin binding.
FT                                {ECO:0000269|PubMed:18635536}.
FT   DISULFID     46    137
FT   DISULFID     48     64
FT   DISULFID     63    117
FT   DISULFID     69    144
FT   DISULFID     70    110
FT   DISULFID     79    103
FT   DISULFID     97    108
FT   VARIANT      19     19       H -> Y (in dbSNP:rs11573162).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018953.
FT   MUTAGEN      49     49       G->S: No effect on integrin binding; when
FT                                associated with K-68.
FT                                {ECO:0000269|PubMed:25398877}.
FT   MUTAGEN      62     62       R->E: No effect on integrin binding.
FT                                {ECO:0000269|PubMed:18635536}.
FT   MUTAGEN      67     67       H->Q: Catalytically inactive but does not
FT                                affect integrin binding.
FT                                {ECO:0000269|PubMed:18635536,
FT                                ECO:0000269|PubMed:25398877}.
FT   MUTAGEN      68     68       D->K: No effect on integrin binding; when
FT                                associated with S-49.
FT                                {ECO:0000269|PubMed:25398877}.
FT   MUTAGEN      73     73       R->E: Slightly reduced integrin binding.
FT                                {ECO:0000269|PubMed:18635536}.
FT   MUTAGEN      94     94       R->E: Moderately reduced integrin
FT                                binding. Greatly reduced integrin binding
FT                                but no effect on catalytic activity; when
FT                                associated with E-120.
FT                                {ECO:0000269|PubMed:18635536,
FT                                ECO:0000269|PubMed:25398877}.
FT   MUTAGEN     120    120       R->E: Moderately reduced integrin
FT                                binding. Greatly reduced integrin binding
FT                                but no effect on catalytic activity; when
FT                                associated with E-94.
FT                                {ECO:0000269|PubMed:18635536,
FT                                ECO:0000269|PubMed:25398877}.
FT   CONFLICT     12     12       I -> Y (in Ref. 4; AAT73043).
FT                                {ECO:0000305}.
FT   HELIX        22     33       {ECO:0000244|PDB:3U8I}.
FT   HELIX        37     40       {ECO:0000244|PDB:3U8I}.
FT   TURN         41     43       {ECO:0000244|PDB:3U8I}.
FT   TURN         45     47       {ECO:0000244|PDB:3U8I}.
FT   STRAND       48     50       {ECO:0000244|PDB:3U8I}.
FT   HELIX        59     76       {ECO:0000244|PDB:3U8I}.
FT   STRAND       81     83       {ECO:0000244|PDB:1POE}.
FT   STRAND       88     91       {ECO:0000244|PDB:3U8I}.
FT   STRAND       94     97       {ECO:0000244|PDB:3U8I}.
FT   HELIX       102    120       {ECO:0000244|PDB:3U8I}.
FT   HELIX       122    124       {ECO:0000244|PDB:3U8I}.
FT   HELIX       127    129       {ECO:0000244|PDB:3U8I}.
FT   HELIX       134    136       {ECO:0000244|PDB:3U8I}.
SQ   SEQUENCE   144 AA;  16083 MW;  923C5FA0C6979CDA CRC64;
     MKTLLLLAVI MIFGLLQAHG NLVNFHRMIK LTTGKEAALS YGFYGCHCGV GGRGSPKDAT
     DRCCVTHDCC YKRLEKRGCG TKFLSYKFSN SGSRITCAKQ DSCRSQLCEC DKAAATCFAR
     NKTTYNKKYQ YYSNKHCRGS TPRC
//
